Development of porphyria cutanea tarda in a hemodialysis patient after reactivation of hepatitis C virus infection.
Cases of porphyria cutanea tarda (PCT) are occasionally reported in hemodialysis patients. Recently, hepatitis C virus has been recognized as a precipitating factor of PCT. The activity of the liver disease may be critical for the appearance of PCT. In this regard, liver disease reactivation after treatment with interferon alpha (IFN-alpha) is a well-known phenomenon. We report the case of a hemodialysis patient who developed PCT coincidentally with reactivation of liver disease, immediately after treatment with IFN-alpha. Therefore, in the present case, reactivation of hepatitis after IFN-alpha withdrawal could be the triggering factor. The occurrence of a bout of PCT should be considered as a possible complication at the end of IFN-alpha therapy, if reactivation of the disease exists.
Albalate
M
M
Centro de Diálisis Santa Engracia, Fundación Renal Iñigo Alvárez de Toledo, Madrid, España.
Fariñas
M C
MC
Octavio
J G
JG
Perez
J H
JH
Goicoechea
M
M
Caramelo
C
C
D000998:Antiviral Agents / Q000627:therapeutic use; D006526:Hepatitis C / Q000150:complications* / Q000378:metabolism; D006801:Humans; D006974:Hypertension, Malignant / Q000150:complications; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007501:Iron / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D017119:Porphyria Cutanea Tarda / Q000188:drug therapy / Q000209:etiology*; D011994:Recombinant Proteins; D006435:Renal Dialysis
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007501:Iron